the fy21 defense appropriations act provides funding to the department of defense neurofibromatosis research program (nfrp) to support innovative, high-impact neurofibromatosis (nf) research. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).
the fy21 nfrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.
areas of emphasis: the nfrp encourages applications that specifically address the critical needs of the nf community in one or more of the fy21 areas of emphasis. not all areas of emphasis are applicable to each award mechanism offered by the fy21 nfrp. if the proposed research project does not address one of the fy21 areas of emphasis, justification that the proposed research project addresses an important problem related to nf research and/or patient care should be provided. applications submitted to the fy21 nfrp must address one or more of the following areas of emphasis:
- biomarker discovery, utility, development, and validation
- non-tumor manifestations not limited to:
o pain
o cognitive manifestations
o sleep
- heterogeneity of nf-related tumors
- novel disease and treatment response markers using genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches
- preclinical efficacy studies
- target identification, drug discovery
- nutritional, environmental, and other modifiers of nf
- health services research
https://cdmrp.army.mil/funding/nfrp
clinical trial award – letter of intent due july 8, 2021
- must be at or above the level of assistant professor
(or equivalent). - supports research with the potential to have a major impact on the treatment or management of nf.
- funds phase 0, 1, or 2 clinical trials relevant to nf and/or schwannomatosis. combinations of phases are permitted.
- must support a clinical trial and may not be used for preclinical research studies.
- the maximum period of performance is 4 years.
- the maximum allowable funding for the entire period of performance is $800,000 in direct costs ($1,000,000 in direct costs if requesting the qualified organizational collaboration option).
- indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
exploration – hypothesis development award – letter of intent due july 8, 2021
- investigators at all academic levels (or equivalent).
- supports the initial exploration of innovative, high-risk, high-gain concepts and potentially groundbreaking concepts in nf research.
- preliminary and/or published data are encouraged but not required.
- clinical trials are not allowed
- the maximum period of performance is 2 years.
- the maximum allowable funding for the entire period of performance is $100,000 in direct costs.
- indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
investigator-initiated research award – letter of intent due july 8, 2021
must be an investigator at or above the level of assistant professor (or equivalent) who plans to commit at least a 10% level of effort for each budget period for the entirety of the award.
- supports highly rigorous, high-impact research with the potential to make an important contribution to nf research and/or patient care.
- preliminary and/or published data relevant to nf are required.
- optional features: applications meeting criteria identified in the program announcement may apply for a higher level of funding for the following options: qualified collaborator and/or nf open science initiative (nf-osi).
- clinical trials are not allowed.
- the maximum period of performance is 3 years.
- the maximum allowable funding for the entire period of performance is $525,000 in direct costs.
- the maximum allowable funding for applications including either the optional qualified collaborator or the nf‑osi option is $575,000 in direct costs.
- the maximum allowable funding for applications including both the optional qualified collaborator option and the nf-osi option is $625,000 in direct costs.
- indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
early investigator research award – letter of intent due july 8, 2021
- be involved in a postdoctoral training or medical residency program; and
- possess at least 1 and up to 4 years of continuous postdoctoral research experience by application submission deadline; and
- possess a doctoral degree (i.e., ph.d., m.d./ph.d., d.o./ph.d.) or a clinical doctoral degree (i.e., m.d./d.o. or ph.d. in a clinical discipline) from an accredited organization or program.
- supports nf-focused research opportunities for individuals in the early stages of their careers.
- investigators must have a designated mentor who is an experienced nf researcher.
- the maximum period of performance is 2 years.
- the maximum allowable funding for the entire period of performance is $200,000 in direct costs.
- indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
synergistic idea development award – letter of intent due july 8, 2021
must be an investigator at or above the level of assistant professor (or equivalent) who plans to commit at least a 10% level of effort for each budget period throughout the entirety of the award.
- supports new ideas that represent synergistic approaches involving two or three principal investigators (pis) (initiating pis and pi[s]) to address a central problem or question in nf research.
- preliminary and/or published data are required.
- clinical trials are not allowed.
- the maximum period of performance is 3 years.
- the maximum allowable funding for the entire period of performance is $200,000,000 in direct costs.
a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website. the application package containing the required forms for each award mechanism will also be found on grants.gov. a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.
for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org. for more information about the nfrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).
point of contact:
cdmrp help desk
301-682-5507
help@ebrap.org